Overview
IAVI W001 trial. 664gp140. W001’ will test the vaccine candidate dubbed BG505 SOSIP — a molecule cloned to look exactly as the HIV one — on Kenyan volunteers to check for safety and efficacy.
Sponser
International AIDS Vaccine Initiative
Principal Investigator
Abstract
The BG505 SOSIP.664 gp140 trimer was engineered by a team directed by John P. Moore, Ph.D., at the Weill Cornell Medical College, Rogier Sanders, Ph.D., now at the University of Amsterdam Academic Medical Center, and Andrew B. Ward, Ph.D., and Ian A. Wilson, D.Phil., at Scripps Research. The outcome of their work was an important advance in stabilizing the highly fragile Env protein in a native-like configuration.
Collaborators in the trial include the Fred Hutchinson Cancer Research Center, Seattle HIV Vaccine Trials Unit; Kenya AIDS Vaccine Initiative-Institute of Clinical Research, University of Nairobi, Kenya (KAVI-ICR, Nairobi); Massachusetts General Hospital, Translational and Clinical Research Center (Boston); and the pharmaceutical company GSK.
